Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Pulmatrix (PULM) Research & Development (2016 - 2025)

Pulmatrix's Research & Development history spans 13 years, with the latest figure at -$3000.0 for Q4 2025.

  • For Q4 2025, Research & Development fell 150.0% year-over-year to -$3000.0; the TTM value through Dec 2025 reached $38000.0, down 99.47%, while the annual FY2025 figure was $38000.0, 99.47% down from the prior year.
  • Research & Development for Q4 2025 was -$3000.0 at Pulmatrix, down from $8000.0 in the prior quarter.
  • Across five years, Research & Development topped out at $5.3 million in Q3 2022 and bottomed at -$3000.0 in Q4 2025.
  • The 5-year median for Research & Development is $3.7 million (2021), against an average of $2.8 million.
  • The largest annual shift saw Research & Development skyrocketed 50.96% in 2022 before it crashed 150.0% in 2025.
  • A 5-year view of Research & Development shows it stood at $3.0 million in 2021, then surged by 50.96% to $4.5 million in 2022, then dropped by 21.29% to $3.5 million in 2023, then crashed by 99.83% to $6000.0 in 2024, then plummeted by 150.0% to -$3000.0 in 2025.
  • Per Business Quant, the three most recent readings for PULM's Research & Development are -$3000.0 (Q4 2025), $8000.0 (Q3 2025), and $14000.0 (Q2 2025).